Related Experiment Videos
Type-common and type-specific monoclonal antibody to herpes simplex virus type 1
Infection and Immunity
|August 1, 1980
Summary
Researchers developed hybridoma cell lines producing antibodies against herpes simplex virus (HSV). These antibodies target specific HSV glycoproteins, offering potential for new diagnostic and therapeutic strategies against HSV infections.
Area of Science:
- Immunology
- Virology
- Molecular Biology
Background:
- Herpes simplex virus (HSV) infections are a significant public health concern.
- Developing effective neutralizing antibodies against HSV is crucial for therapeutic interventions.
- Understanding the specific viral targets of neutralizing antibodies can guide vaccine and drug development.
Purpose of the Study:
- To generate hybridoma cell lines producing monoclonal antibodies against herpes simplex virus (HSV).
- To characterize the specificity and neutralizing capacity of these antibodies against different HSV types and glycoproteins.
- To investigate the clonal origin and immunoglobulin subclass of the antibody-producing hybridomas.
Main Methods:
- Production of hybridoma cells by fusing mouse myeloma cells with spleen cells from HSV-type 1 primed mice.
- Screening of hybridoma clones for antibody production against HSV.
- Characterization of antibody specificity through immunoprecipitation of viral glycoproteins (Glycoprotein C and D).
- Neutralization assays to assess antibody efficacy against HSV type 1, HSV type 2, and HSV-1 strain MP.
Main Results:
- Five hybridoma clones producing neutralizing antibodies against HSV type 1 were successfully generated.
- Two clones (HC1, HC2) produced antibodies targeting Glycoprotein C, neutralizing HSV type 1 but not HSV type 2 or Glycoprotein C-deficient HSV-1.
- Three clones (HD1, HD2, HD3) produced antibodies targeting Glycoprotein D; HD1 and HD2 neutralized both HSV types, while HD3 neutralized only HSV type 1.
- Antibodies targeting Glycoprotein C and type-common Glycoprotein D antibodies were independently derived and belonged to different immunoglobulin subclasses.
Conclusions:
- Hybridoma technology can effectively generate monoclonal antibodies targeting specific HSV glycoproteins.
- Antibodies against Glycoprotein C are type-specific, while some antibodies against Glycoprotein D exhibit type-common neutralizing activity.
- The distinct origins and immunoglobulin subclasses of the antibodies suggest diverse B cell responses to HSV infection.